We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GR Defect in Peripheral Blood Mononuclear Cells in COPD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00159237
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : August 13, 2008
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Imperial College London

Brief Summary:
T.to investigate a possible mechanism of the glucocorticosteroid receptors (GR) defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR- binding, interleukin production (IL-6/IL-8) and MKP-1 expression in peripheral blood mononuclear cells blood (PBMC)

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Procedure: blood test

Study Type : Observational
Estimated Enrollment : 30 participants
Time Perspective: Prospective
Official Title: GR Defect in Peripheral Blood Mononuclear Cells in COPD
Study Start Date : February 2005
Estimated Study Completion Date : December 2008




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with severe (stage III, Gold) to very severe (stage IV, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers
  • Written informed consent

Exclusion Criteria:

  • Current upper respiratory tract infections
  • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
  • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159237


Locations
United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
AstraZeneca
Investigators
Principal Investigator: Sergei A Kharitonov, MD PhD Imperial College London

ClinicalTrials.gov Identifier: NCT00159237     History of Changes
Other Study ID Numbers: D5899N00007
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: August 13, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases